Kristopher Paolino, MD
Infectious Disease · Syracuse, NYNPI 1205952280
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,798 of the $4,798 with a category attached, or 100.0%. Dynavax Technologies Corporation accounts for 69.3% of it on its own, with 1 other manufacturer making up the rest.
Across 8 payments — averaging $599.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dynavax Technologies Corporation$3K
- Regeneron$1K
Across 139 payments — averaging $10,089 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$667K
- Sanofi Pasteur Inc.$317K
- Regeneron$191K
- Roche Diagnostics Operations, Inc.$82K
- Eli Lilly$73K
- Janssen Research & Development, LLC$38K
- plus $34K from 2 others
What the payments were for
- Consulting fees$4,798100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dynavax Technologies Corporation | 7 | $3,323 |
| Regeneron | 1 | $1,475 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Heplisav-B$2,385
How this compares
$4,798 in reported general payments places this provider in the 85th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 45 | $1,445 |
| CefuroximeCefuroxime Axetil | 17 | $977 |
| Bupropion XlBupropion Hcl | 60 | $919 |
| Doxycycline Hyclate | 18 | $345 |
| Gabapentin | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Syracuse
- Stephen ThomasSyracuse$294K
- Timothy EndySyracuse$19K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Andre BrutusBrooklyn$303K
- Glenn TurettFlushing$253K
- Genovefa PapanicolaouNew York$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.